Mitochondrial DNA Variant Panel

Key Information

TAT:

5 weeks

Price:

$1,600

CPT Code(s):

81479

Test Code:

DMVP

Mitochondrial DNA Variant Panel

The Mitochondrial DNA Variant Panel includes 96 mitochondrial DNA variants with known phenotypes for patients with a clinical suspicion of a mitochondrial disorder. This test can also confirm a diagnosis and identify disease-causing variants within a family to facilitate carrier testing. The variants below are included in the analysis. Please note that the variant “m.7445A>G” is located at the boundary of two genes, MT-CO1 and MT-TS1, and is commonly considered as two variants.

m.583G>A; m.616T>C; m.1494C>T; m.1555A>G; m.1606G>A; m.1630A>G; m.1644G>A; m.3243A>G; m.3243A>T; m.3256C>T; m.3258T>C; m.3260A>G; m.3271T>C; m.3273del; m.3280A>G; m.3291T>C; m.3302A>G; m.3303C>T; m.3376G>A; m.3460G>A; m.3635G>A; m.3697G>A; m.3700G>A; m.3733G>A; m.3890G>A; m.3902_3908inv; m.4171C>A; m.4298G>A; m.4300A>G; m.4308G>A; m.4332G>A; m.4450G>A; m.5521G>A; m.5537_5538insT; m.5650G>A; m.5690A>G; m.5703G>A; m.5728T>C; m.7445A>G; m.7471_7472insC; m.7497G>A; m.7510T>C; m.7511T>C; m.8306T>C; m.8313G>A; m.8340G>A; m.8344A>G; m.8356T>C; m.8363G>A; m.8528T>C; m.8851T>C; m.8969G>A; m.8993T>C; m.8993T>G; m.9035T>C; m.9155A>G; m.9176T>C; m.9176T>G; m.9185T>C; m.9191T>C; m.9205_9206del; m.10010T>C; m.10158T>C; m.10191T>C; m.10197G>A; m.10663T>C; m.11777C>A; m.11778G>A; m.12147G>A; m.12201T>C; m.12258C>A; m.12276G>A; m.12294G>A; m.12315G>A; m.12316G>A;
m.12706T>C; m.13042G>A; m.13051G>A; m.13094T>C; m.13379A>G; m.13513G>A; m.13514A>G; m.14453G>A; m.14459G>A; m.14482C>A; m.14482C>G; m.14484T>C; m.14487T>C; m.14495A>G; m.14568C>T; m.14674T>C; m.14709T>C; m.14710G>A; m.14849T>C; m.15579A>G; m.15990C>T;

Aminoglycoside-induced hearing loss, Ataxia myoclonus mental deterioration and deafness, Ataxia syndromes, Cardiac and multi-organ dysfunction, Cardiomyopathy, Chronic progressive external ophthalmoplegia (CPEO), Diabetes and deafness, Dystonia, Hypertrophic cardiomyopathy, Leber hereditary optic neuropathy (LHON), Mitochondrial encephalomyopathy, Mitochondrial myopathy plus diabetes mellitus and deafness, Myoclonic epilepsy and ragged red fibers (MERRF), Neurogenic muscle weakness ataxia retinitis pigmentosa, Progressive encephalopathy, Retinitis pigmentosa and sensorineural hearing loss, Reversible COX deficiency myopathy

Clinical Information

Mitochondrial disorders represent a clinically heterogeneous group of conditions caused by pathogenic variants in either nuclear or mitochondrial DNA (mtDNA). Some mitochondrial disorders affect a single organ while most involve multiple organ systems. Mitochondrial disorders may present at any age and often present with prominent neurologic and myopathic features. Mitochondrial disorders have variable penetrance and severity of symptoms depending on the level of mutant mitochondria, or heteroplasmy, within a given individual or tissue type.

Technical Information

This panel is performed by Next Generation Sequencing.

Variants included in this panel account for >80% of MELAS, ~90% of MERRF, ~95% of LHON, ~ 50% of NARP, and ~ 20% of Leigh Syndrome cases. Individuals with Pearson syndrome or KSS and some patients with CPEO have large-scale (2-10 kb) mtDNA deletions, which will not be detected by the protocol used for this test.

This test may not detect variants with a heteroplasmy of less than 10% using NGS. It is not possible to confirm all reported variants by Sanger sequencing because levels of mutant heteroplasmy 20% or lower may not be detected by Sanger. Additionally, levels of mutant heteroplasmy above 80% will appear homoplasmic by Sanger sequencing. Although this test is capable of collecting data on variants at other loci in the mitochondrial genome, it does not evaluate for variants other than those listed above. Additional variants which may be present in the patient are not reported with this test.

Large deletions or duplications in the mitochondrial genome are not identified with the current sequencing protocol. As heteroplasmy levels vary from tissue to tissue, a negative blood test cannot completely rule out the chance that an individual carries a mtDNA variant that is either at very low heteroplasmy levels in blood or present in a different tissue type.

Specimen Requirements

  • The preferred sample type is 3-5 ml of peripheral blood collected in an EDTA (purple top) tube. Extracted DNA and saliva are also accepted for this test. Blood and saliva kits are available upon request.
  • Send approximately 5µg of extracted DNA at a requested concentration of 90-130 ng/µl.
  • Saliva samples must be submitted in an approved saliva kit.

Transport Instructions

  • The blood specimen should be kept at room temperature and delivered via overnight shipping. If shipment is delayed by one or two days, the specimen should be refrigerated and shipped at room temperature. Do not freeze the specimen. Samples collected on Friday can be safely designated for Monday delivery.
  • Extracted DNA should be sent at room temperature via overnight delivery.
  • Saliva is stable at room temperature and can be delivered via overnight or ground shipping.

Connect With Our Experts

Call 1-800-473-9411 to speak with our team of laboratory genetic counselors for questions or additional information.

Robin Fletcher, MS, CGC
Falecia Thomas, MS, CGC
Alex Finley, MS, CGC